CMBA
DNA icon

C.M. Bidwell & Associates’s Ginkgo Bioworks DNA Stock Holding History

C.M. Bidwell & Associates’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5
Closed -$49 – 464
2024
Q4 		$49 Hold
5
– – ﹤0.01% 483
2024
Q3 		$41 Sell
5
-1
-17% -$10 ﹤0.01% 499
2024
Q2 		$78 Hold
6
– – ﹤0.01% 474
2024
Q1 		$271 Hold
6
– – ﹤0.01% 471
2023
Q4 		$395 Sell
6
-19
-76% -$1.16K ﹤0.01% 460
2023
Q3 		$1.81K Hold
25
– – ﹤0.01% 475
2023
Q2 		$1.87K Hold
25
– – ﹤0.01% 475
2023
Q1 		$1.33K Hold
25
– – ﹤0.01% 487
2022
Q4 		$1.7K Buy
25
+19
+317% +$1.75K ﹤0.01% 466
2022
Q3 		$1K Hold
6
– – ﹤0.01% 450
2022
Q2 		$1K Hold
6
– – ﹤0.01% 456
2022
Q1 		$1K Buy
+6
New +$1.17K ﹤0.01% 494

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

C.M. Bidwell & Associates's DNA Position: Q1 2025 in Review

C.M. Bidwell & Associates sold out of Ginkgo Bioworks (DNA) in Q1 2025, closing a stake of 5 shares — an estimated $49 sold.

C.M. Bidwell & Associates first reported a position in DNA in Q1 2022 and held it in 12 quarters. The position peaked at $1.87K in Q2 2023. 167 funds tracked by Wall St. Rank hold DNA as of Q1 2025.

  • C.M. Bidwell & Associates reported no remaining Ginkgo Bioworks position as of Q1 2025 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 5 Ginkgo Bioworks shares in Q1 2025, an estimated $49.
  • C.M. Bidwell & Associates first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 12 quarters.
  • C.M. Bidwell & Associates's Ginkgo Bioworks position peaked at $1.87K in Q2 2023.
  • 167 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2025.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2025, filed 15 May 2025.